Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shineco Plans to Acquire 51% of Taiwan's Mayah Biological

publication date: May 4, 2021

Shineco, a China herbal medicine company, announced plans to acquire a 51% stake in Taiwan's Mayah Biological Holdings. Mayah describes itself as a biotech that focuses on novel chemical and biomedicine products in pre-clinical and clinical stages. Its lead product has completed a Phase II trial, with a second cancer therapy ready to start a Phase II trial, and three other cancer drugs about to enter clinical development. At the moment, the two companies are doing their due diligence, with no guarantee that an actual transaction will take place. More details....

Stock Symbol: (NSDQ: TYHT)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.